Cargando…

Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients

BACKGROUND: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. OBJECTIVES: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. PATIENTS AND METHODS: Thirty-one naïve patients with chronic hepat...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghemo, Alessio, Rumi, Maria Grazia, Monico, Sara, Banderali, Matteo, Russo, Antonio, Ottaviani, Francesco, Vigano, Mauro, D’Ambrosio, Roberta, Colombo, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269061/
https://www.ncbi.nlm.nih.gov/pubmed/22308157
http://dx.doi.org/10.5812/kowsar.1735143X.733
_version_ 1782222442977034240
author Aghemo, Alessio
Rumi, Maria Grazia
Monico, Sara
Banderali, Matteo
Russo, Antonio
Ottaviani, Francesco
Vigano, Mauro
D’Ambrosio, Roberta
Colombo, Massimo
author_facet Aghemo, Alessio
Rumi, Maria Grazia
Monico, Sara
Banderali, Matteo
Russo, Antonio
Ottaviani, Francesco
Vigano, Mauro
D’Ambrosio, Roberta
Colombo, Massimo
author_sort Aghemo, Alessio
collection PubMed
description BACKGROUND: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. OBJECTIVES: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. PATIENTS AND METHODS: Thirty-one naïve patients with chronic hepatitis C consecutively received PegIFN-α2a (180 μg/week) plus Rbv (800–1200 mg/day). The controls were 10 patients with chronic hepatitis B who received PegIFN-α2a (180 μg/week). During treatment and follow-up, all patients underwent basal and masticatory stimulated sialometry,otorhinolaryngoiatric (ORL) examination, and a questionnaire survey to subjectively assess symptoms of oral dryness. RESULTS: Twenty-seven patients on PegIFN/Rbv and 4 on PegIFN (87% vs. 40%, P = 0.006) reported xerostomia. Thirty patients on PegIFN/Rbv combination therapy and 2 patients on monotherapy had ORL signs of salivary gland hypofunction (97% vs. 20%, P < 0.0001).Mean basal (A) and stimulated (B) salivary flow rates (mL/min) progressively decreased during PegIFN/Rbv treatment (A, 0.49 at baseline vs. 0.17 at the end of treatment, P < 0.0001; B, 1.24 at baseline vs. 0.53 at the end of treatment, P = 0.0004). At week 24 following PegIFN/Rbv treatment, salivary flow rates were similar to baseline (A, 0.53 at the end of follow-up vs. 0.49 at baseline; B, 1.19 at the end of follow-up vs. 1.24 at baseline). Salivary function was unaffected in monotherapy patients. CONCLUSIONS: Rbv causes salivary gland hypofunction in hepatitis C patients receiving PegIFN/Rbv therapy, which promptly reverts to normal upon cessation of treatment.
format Online
Article
Text
id pubmed-3269061
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-32690612012-02-03 Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients Aghemo, Alessio Rumi, Maria Grazia Monico, Sara Banderali, Matteo Russo, Antonio Ottaviani, Francesco Vigano, Mauro D’Ambrosio, Roberta Colombo, Massimo Hepat Mon Brief Report BACKGROUND: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. OBJECTIVES: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. PATIENTS AND METHODS: Thirty-one naïve patients with chronic hepatitis C consecutively received PegIFN-α2a (180 μg/week) plus Rbv (800–1200 mg/day). The controls were 10 patients with chronic hepatitis B who received PegIFN-α2a (180 μg/week). During treatment and follow-up, all patients underwent basal and masticatory stimulated sialometry,otorhinolaryngoiatric (ORL) examination, and a questionnaire survey to subjectively assess symptoms of oral dryness. RESULTS: Twenty-seven patients on PegIFN/Rbv and 4 on PegIFN (87% vs. 40%, P = 0.006) reported xerostomia. Thirty patients on PegIFN/Rbv combination therapy and 2 patients on monotherapy had ORL signs of salivary gland hypofunction (97% vs. 20%, P < 0.0001).Mean basal (A) and stimulated (B) salivary flow rates (mL/min) progressively decreased during PegIFN/Rbv treatment (A, 0.49 at baseline vs. 0.17 at the end of treatment, P < 0.0001; B, 1.24 at baseline vs. 0.53 at the end of treatment, P = 0.0004). At week 24 following PegIFN/Rbv treatment, salivary flow rates were similar to baseline (A, 0.53 at the end of follow-up vs. 0.49 at baseline; B, 1.19 at the end of follow-up vs. 1.24 at baseline). Salivary function was unaffected in monotherapy patients. CONCLUSIONS: Rbv causes salivary gland hypofunction in hepatitis C patients receiving PegIFN/Rbv therapy, which promptly reverts to normal upon cessation of treatment. Kowsar 2011-11 2011-11-30 /pmc/articles/PMC3269061/ /pubmed/22308157 http://dx.doi.org/10.5812/kowsar.1735143X.733 Text en Copyright © 2011, Kowsar M.P. Co. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Aghemo, Alessio
Rumi, Maria Grazia
Monico, Sara
Banderali, Matteo
Russo, Antonio
Ottaviani, Francesco
Vigano, Mauro
D’Ambrosio, Roberta
Colombo, Massimo
Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
title Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
title_full Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
title_fullStr Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
title_full_unstemmed Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
title_short Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
title_sort ribavirin impairs salivary gland function during combination treatment with pegylated interferon alfa-2a in hepatitis c patients
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269061/
https://www.ncbi.nlm.nih.gov/pubmed/22308157
http://dx.doi.org/10.5812/kowsar.1735143X.733
work_keys_str_mv AT aghemoalessio ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients
AT rumimariagrazia ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients
AT monicosara ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients
AT banderalimatteo ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients
AT russoantonio ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients
AT ottavianifrancesco ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients
AT viganomauro ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients
AT dambrosioroberta ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients
AT colombomassimo ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients